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Background:  Patients with acute cardiogenic pulmonary edema (ACPE) have frequently preserved left ventricular systolic function (PSF). We 
assessed the hypothesis that myocardial damage and ventricular overload could have additive impact to stratifying risk in this setting.
Methods:  Between Oct/00 and Dec/06, 182 patients admitted to the hospital for ACPE and PSF (LVEF ≥40%), in the absence of acute coronary 
syndrome, were enrolled in a retrospective, multicenter, collaborative study. Blood samples obtained during hospitalization were assayed for cardiac 
troponin T (cTnT), and for NT-proBNP (N=10) or BNP (n=172).
Results:  Mean age was 78±9 years, 48% were male and 39% had ischemic etiology. During the follow up (143±63 days) the incidence of the 
combined end point (rehospitalization for acute heart failure or death) was 31%. The area under ROC curves for predicting end points for cTnT, NT-
proBNP and BNP was 0.67, 0.84 and 0.68, and cut-off were ≥0.030 ng/mL, ≥3000 pg/mL and ≥480 pg/mL, respectively. According to status above 
or below cut-off, population was classified as cTnT(+) or (-), and natriuretic peptides (NP)(+) or (-). The prevalence of cTnT(+) was 36% and NP(+) 
was 50%. Patients with events were older (81±8 vs 77±9 years,p=0.010), with higher prevalence of class III-IV (43 vs 23%, 0.008), coronary artery 
disease (50 vs 34%, 0.043), renal failure (20 vs 8%, 0.023), cTnT(+) (57 vs 26%, <0.0001) and NP(+) (77 vs 37%, <0.0001). In Cox-proportional 
hazard model, the variables associated with events were age (HR=1.038; 95%CI=1.001-1.078; p=0.049), cTnT(+)(2.3;1.3-4.0;0.006) and NP(+)
(2.9;1.5-5.7;0.002). The 6-months free events survival was 90% with both markers (-), 68% with only cTnT (+), 61% with only NP (+) and 44% with 
cTnT(+) and NP(+) (p<0.00001). Compared with subjects with both biomarkers (-), the presence of cTnT or NP(+) was associated with a risk of 3.5 
(95%CI=1.4-8.5), whereas both positve markers increased the risk 7.3 times (95%CI=3.0-18.2).
Conclusions:  cTnT and NP are powerful markers of poor outcome in ACPE and PSF. The additive value of combined use suggests that the risk-
stratification in this setting should include both, a marker of myocardial damage and one of LV overload.
